knowledge -WSS

knowledge

author：Wikipedia 2025-08-28 13:04:13 - browse：6364

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Why you get paid to donate plasma but not blood

explore

focus

WSS

More hospitals are billing patients as online messages surge

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Doctors push to include dialysis machines in emergency stockpile

Manchin plays down potential 3rd

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

focus

knowledge

hotspot

New air purifier tech could be key to improving indoor air quality

Feed a cold, starve a fever? Here’s what science says

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Robert Kennedy Jr.'s presidential campaign attracts GOP

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Why you get paid to donate plasma but not blood

Activists slam private health insurers over coverage restrictions

St. Louis police protesters begin picking up checks in $4.9 million settlement

Guidelines to prevent youth baseball injuries need more muscle

Flagship, Pfizer team up in deal worth up to $7 billion

focus

Kansas bar where gunfire wounded 9 last month closes permanently

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Twill hunts for pharma partner to market its depression app

More hospitals are billing patients as online messages surge

Many breast cancer patients receive more radiation than needed

Feed a cold, starve a fever? Here’s what science says

explore

leisure time

focus

entertainment